Medera Inc. ('Medera'), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the final patient has ...

Medera has completed patient dosing in Cohort B of its ongoing MUSIC-HFpEF Phase I/IIa study of SRD-002 for heart failure ...

Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...

Why it is so dangerous, how it is diagnosed and how to help prevent it ...

A doctor has explained the various health benefits that you may feel after just a month of not drinking alcohol – and every ...

SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...

Idorsia receives approval from Health Canada for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral ant ...

Social determinants of health (SDOH) were found to be associated with increased risk of heart failure (HF) and ventricular arrhythmias (VA) in patients with hypertrophic cardiomyopathy (HCM), ...

Idorsia receives approval from Health Canada for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral ...

And what to do about it by Thomas Keil and Marianna Zangrillo In their pursuit of strong performance, CEOs and executives often overlook a critical factor in organizational success: the health of ...